Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Crinetics Pharmaceuticals has reported Accumulated Depreciation over the past 9 years, most recently at $9.6 million for Q2 2025.

  • Quarterly results put Accumulated Depreciation at $9.6 million for Q2 2025, up 53.84% from a year ago — trailing twelve months through Jun 2025 was $9.6 million (up 53.84% YoY), and the annual figure for FY2024 was $7.7 million, up 52.57%.
  • Accumulated Depreciation for Q2 2025 was $9.6 million at Crinetics Pharmaceuticals, up from $8.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for CRNX hit a ceiling of $9.6 million in Q2 2025 and a floor of $3.0 million in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $4.6 million (2023), compared with a mean of $5.2 million.
  • Biggest five-year swings in Accumulated Depreciation: soared 62.02% in 2021 and later rose 16.95% in 2023.
  • Crinetics Pharmaceuticals' Accumulated Depreciation stood at $3.5 million in 2021, then increased by 17.36% to $4.1 million in 2022, then grew by 24.09% to $5.1 million in 2023, then surged by 52.57% to $7.7 million in 2024, then grew by 23.98% to $9.6 million in 2025.
  • The last three reported values for Accumulated Depreciation were $9.6 million (Q2 2025), $8.6 million (Q1 2025), and $7.7 million (Q4 2024) per Business Quant data.